Mustang Bio (MBIO) Competitors $1.52 -0.01 (-0.33%) As of 02:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBIO vs. JSPR, KLRS, TELO, IPSC, ANVS, STTK, KLTO, NBRV, FGEN, and GRCEShould you be buying Mustang Bio stock or one of its competitors? The main competitors of Mustang Bio include Jasper Therapeutics (JSPR), Kalaris Therapeutics (KLRS), Telomir Pharmaceuticals (TELO), Century Therapeutics (IPSC), Annovis Bio (ANVS), Shattuck Labs (STTK), Klotho Neurosciences (KLTO), Nabriva Therapeutics (NBRV), FibroGen (FGEN), and Grace Therapeutics (GRCE). These companies are all part of the "pharmaceutical products" industry. Mustang Bio vs. Its Competitors Jasper Therapeutics Kalaris Therapeutics Telomir Pharmaceuticals Century Therapeutics Annovis Bio Shattuck Labs Klotho Neurosciences Nabriva Therapeutics FibroGen Grace Therapeutics Jasper Therapeutics (NASDAQ:JSPR) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends. Does the media prefer JSPR or MBIO? In the previous week, Jasper Therapeutics and Jasper Therapeutics both had 1 articles in the media. Jasper Therapeutics' average media sentiment score of 0.70 beat Mustang Bio's score of 0.44 indicating that Jasper Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Jasper Therapeutics Positive Mustang Bio Neutral Which has preferable earnings & valuation, JSPR or MBIO? Jasper Therapeutics is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJasper TherapeuticsN/AN/A-$71.27M-$6.01-0.45Mustang BioN/AN/A-$15.75M-$78.00-0.02 Which has more volatility and risk, JSPR or MBIO? Jasper Therapeutics has a beta of 2.77, indicating that its share price is 177% more volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500. Do institutionals & insiders have more ownership in JSPR or MBIO? 79.9% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 10.0% of Mustang Bio shares are held by institutional investors. 4.6% of Jasper Therapeutics shares are held by company insiders. Comparatively, 0.2% of Mustang Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts recommend JSPR or MBIO? Jasper Therapeutics currently has a consensus target price of $28.75, suggesting a potential upside of 953.11%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Jasper Therapeutics is more favorable than Mustang Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jasper Therapeutics 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60Mustang Bio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is JSPR or MBIO more profitable? Mustang Bio's return on equity of 0.00% beat Jasper Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Jasper TherapeuticsN/A -172.28% -128.34% Mustang Bio N/A N/A -29.49% SummaryJasper Therapeutics beats Mustang Bio on 8 of the 12 factors compared between the two stocks. Get Mustang Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBIO vs. The Competition Export to ExcelMetricMustang BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.04M$3.09B$5.73B$9.81BDividend YieldN/A2.28%6.66%4.48%P/E Ratio-0.0221.0582.3826.51Price / SalesN/A388.53526.77107.89Price / CashN/A43.5325.7028.92Price / Book3.818.0810.636.55Net Income-$15.75M-$53.35M$3.28B$266.04M7 Day Performance-0.33%-0.15%-0.35%-0.79%1 Month Performance3.74%9.24%9.99%6.02%1 Year Performance-89.13%10.70%48.79%21.97% Mustang Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBIOMustang Bio0.3118 of 5 stars$1.53-0.3%N/A-89.1%$11.04MN/A-0.02100Short Interest ↑JSPRJasper Therapeutics2.8152 of 5 stars$2.96+1.0%$28.75+871.3%-87.3%$47.62MN/A-0.4920KLRSKalaris Therapeutics1.2453 of 5 stars$2.51flat$3.00+19.5%N/A$46.94MN/A0.00110Positive NewsAnalyst ForecastTrading HaltedTELOTelomir Pharmaceuticals3.219 of 5 stars$1.46+0.7%$15.00+927.4%-77.1%$46.81MN/A-2.701Short Interest ↓Gap DownIPSCCentury Therapeutics2.836 of 5 stars$0.51-5.5%$3.75+633.6%-72.7%$46.75M$6.59M-1.76170Positive NewsANVSAnnovis Bio2.0354 of 5 stars$2.24-5.5%$18.00+703.6%-72.3%$46.18MN/A-1.103Analyst ForecastSTTKShattuck Labs3.1843 of 5 stars$0.99+3.5%$7.00+604.4%-71.9%$45.99M$5.72M-0.82100News CoverageInsider TradeShort Interest ↑Gap UpKLTOKlotho NeurosciencesN/A$0.75+0.7%N/AN/A$45.96MN/A-1.68N/APositive NewsNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070FGENFibroGen4.4027 of 5 stars$10.63-4.9%$43.00+304.5%+33.3%$45.21M$29.62M-27.97570GRCEGrace Therapeutics2.6074 of 5 stars$3.25flat$12.00+269.2%N/A$44.94MN/A-3.78N/AAnalyst Downgrade Related Companies and Tools Related Companies JSPR Alternatives KLRS Alternatives TELO Alternatives IPSC Alternatives ANVS Alternatives STTK Alternatives KLTO Alternatives NBRV Alternatives FGEN Alternatives GRCE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBIO) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mustang Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mustang Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MBIO Stock Alerts